Trial Profile
Cytolytic activity and immunological responses of TKD activated natural killer cells in patients with colorectal carcinoma and non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2016
Price :
$35
*
At a glance
- Drugs TKD-activated natural killer cells (Primary) ; Interleukin-2
- Indications Carcinoma; Colorectal cancer; Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 14 Jan 2016 New trial record